ArticleMolecular metabolism2019
A reduced form of nicotinamide riboside defines a new path for NAD
Article in Molecular metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 130 citations in OpenAlex.
- Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in mice.Nature communications · 2026Article
- Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights.Nutrients · 2026Review
- Reduced Versus Oxidized NADFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development.Science advances · 2026Review
- Differential regulation of SIRT5 activity by reduced nicotinic acid riboside (NARH).RSC chemical biology · 2026Article
- Modulation of SIRT1/PPARγ pathways and tight junction proteins by nicotinamide riboside under chronic variable stress.Journal of physiology and biochemistry · 2026Article
- Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Precision Nanodelivery Enables Spatiotemporal Control of NAD⁺ Metabolism in Ageing and Disease.International journal of nanomedicine · 2026Review
- Pharmacological profiling of intravenous MP-04: sustained NADFrontiers in pharmacology · 2026Article
- Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis.NAR cancer · 2025Article
- NAD + in fatty liver disease: mechanistic insights and associated targets.Cell biology and toxicology · 2025Review
- Quinolinic acid metabolism may mitigate AKI to CKD transition.bioRxiv : the preprint server for biology · 2025Article
- NADNature metabolism · 2025Review
- Emerging strategies, applications and challenges of targeting NADNature aging · 2025Review
- Mitochondrial Damage and Autophagy Dysregulation in Alzheimer's Disease: Mechanisms and Therapeutic Opportunities.Neurochemical research · 2025Review
- The role of NADnpj metabolic health and disease · 2025Review
- Nicotinamide riboside and nicotinamide mononucleotide facilitate NADScience advances · 2025Article
- Tartary Buckwheat Bran and Fructus Aurantii Combination (TBB-FA): A Promising Therapeutic Approach for Functional Dyspepsia via Modulation of Gut Microbiota, Short-Chain Fatty Acids and Purine Signaling Pathway.Food science & nutrition · 2025Article
- Evolutionary analysis of Quinone Reductases 1 and 2 suggests that NQO2 evolved to function as a pseudoenzyme.Protein science : a publication of the Protein Society · 2024Article
- NADCell communication and signaling : CCS · 2024Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
objectiveA decay in intracellular NAD
methodsThrough a combination of metabolomics and pharmacological approaches, we describe how NRH, a reduced form of NR, serves as a potent NAD
resultsNRH acts as a more potent and faster NAD
conclusionsOur data identify a new pathway for NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.